Mats Wahlstrom

Insider Reports History

Identity
Location
Golden, CO
SEC record
Reporting signature
/s/ Mary Szela, Attorney-in-Fact
SEC evidence
Transaction evidence
Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Holdings reported by Mats Wahlstrom:

Form 4 holding Director

Coherus Oncology, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
112,000
Estimated value
Report date
12 Jun 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

TriSalus Life Sciences, Inc.

Security class
Series A Convertible Preferred Stock
Shares / value
94,750
Estimated value
Report date
10 Feb 2025
Price
Ownership
By Leonard Capital LLC
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Mats Wahlstrom

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .